Your browser doesn't support javascript.
loading
Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13.
Zeng, Mei; Kwiatkowski, Nicholas P; Zhang, Tinghu; Nabet, Behnam; Xu, Mousheng; Liang, Yanke; Quan, Chunshan; Wang, Jinhua; Hao, Mingfeng; Palakurthi, Sangeetha; Zhou, Shan; Zeng, Qing; Kirschmeier, Paul T; Meghani, Khyati; Leggett, Alan L; Qi, Jun; Shapiro, Geoffrey I; Liu, Joyce F; Matulonis, Ursula A; Lin, Charles Y; Konstantinopoulos, Panagiotis A; Gray, Nathanael S.
Afiliación
  • Zeng M; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States.
  • Kwiatkowski NP; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States.
  • Zhang T; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States.
  • Nabet B; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States.
  • Xu M; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States.
  • Liang Y; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States.
  • Quan C; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States.
  • Wang J; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States.
  • Hao M; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States.
  • Palakurthi S; Department of Medicine, Harvard Medical School, Boston, United States.
  • Zhou S; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States.
  • Zeng Q; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States.
  • Kirschmeier PT; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States.
  • Meghani K; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States.
  • Leggett AL; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States.
  • Qi J; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States.
  • Shapiro GI; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States.
  • Liu JF; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States.
  • Matulonis UA; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, United States.
  • Lin CY; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, United States.
  • Konstantinopoulos PA; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, United States.
  • Gray NS; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, United States.
Elife ; 72018 11 13.
Article en En | MEDLINE | ID: mdl-30422115
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Fenilendiaminas / Pirimidinas / Proteína Quinasa CDC2 / Proteínas Proto-Oncogénicas c-myc / Quinasas Ciclina-Dependientes / Antineoplásicos Límite: Animals / Female / Humans Idioma: En Revista: Elife Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Fenilendiaminas / Pirimidinas / Proteína Quinasa CDC2 / Proteínas Proto-Oncogénicas c-myc / Quinasas Ciclina-Dependientes / Antineoplásicos Límite: Animals / Female / Humans Idioma: En Revista: Elife Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos